Monarch Global Health is a Florida-based diagnostic healthcare manufacturer striving to advance healthcare through innovation and testing technology that can lead to improved patient outcomes with quicker diagnostic results without the need for external equipment. Monarch Global Health was established with the primary goal of improving quality, securing timelines, and guaranteeing testing availability in the United States of COVID 19 Antibody and Antigen Test Kits.
Monarch Global Health
ON/GO. COVID-19 ANTIGEN SELF-TEST
Only the fastest, most advanced test is good enough to be called On/Go.
On/Go isn’t simply an FDA authorized rapid antigen test, it’s an easy-to-use, complete diagnostic and management system that operates directly with your phone. Here are the reasons both individuals and institutions will want to choose On/Go instead of the rest.
MANUFACTURING
Monarch Global Health has three manufacturing facilities located in Miami, Ocala, and Cocca Florida. Monarch Global Health facilities are dedicated to the production of COVID-19 testing solutions and are able to assemble over 600,000 tests per day between all three facilities. COVID-19 is caused by a coronavirus called SARS-CoV-2. Older adults and people who have severe underlying medical conditions like heart or lung disease or diabetes seem to be at higher risk for developing more serious complications from COVID-19 illness.
CORE VALUES
Commitment, Consistency, and Community
Monarch Executive Team
Our forward-looking leadership team is made up of dedicated, focused and experienced executives. Working with each other and with our employees worldwide, their knowledge and experience come together to make a difference for all our stakeholders – patients, healthcare providers, employees, investors and communities around the globe.
PRESS & NEWS
- New rat lungworm disease resource to help doctors with diagnosis, treatment
As climate change continues, human cases of rat lungworm disease are anticipated to become more widespread globally, especially in places… Read more » - Expression of p-STAT3 and c-Myc correlates with P2-HNF4α expression in nonalcoholic fatty liver disease (NAFLD)Nonalcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome and is rapidly becoming one of the major causes… Read more »
- New study finds promising treatment for cognitive deficits associated with cholestatic liver diseasePatients with cholestatic liver disease such as primary biliary cholangitis (PBC) can experience significant impairment of bile flow and may… Read more »
English
Portuguese
Spanish